BR112019023074A2 - composição contendo ciclodextrina e bussulfano - Google Patents
composição contendo ciclodextrina e bussulfano Download PDFInfo
- Publication number
- BR112019023074A2 BR112019023074A2 BR112019023074A BR112019023074A BR112019023074A2 BR 112019023074 A2 BR112019023074 A2 BR 112019023074A2 BR 112019023074 A BR112019023074 A BR 112019023074A BR 112019023074 A BR112019023074 A BR 112019023074A BR 112019023074 A2 BR112019023074 A2 BR 112019023074A2
- Authority
- BR
- Brazil
- Prior art keywords
- busulfan
- composition containing
- containing cyclodextrin
- cyclodextrin
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500970P | 2017-05-03 | 2017-05-03 | |
| PCT/US2018/030728 WO2018204535A1 (en) | 2017-05-03 | 2018-05-02 | Composition containing cyclodextrin and busulfan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023074A2 true BR112019023074A2 (pt) | 2020-06-09 |
Family
ID=64014433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023074A BR112019023074A2 (pt) | 2017-05-03 | 2018-05-02 | composição contendo ciclodextrina e bussulfano |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180318249A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3618825A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7204670B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190141244A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110831588B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018263924B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019023074A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3062308A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019013053A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018204535A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109078005B (zh) * | 2018-08-07 | 2021-11-26 | 江苏领航生物科技有限公司 | 一种白消安组合物及其制备方法和应用 |
| CN113679852B (zh) * | 2021-09-13 | 2022-11-15 | 天津师范大学 | 一种水溶性主客体复合物及其制备与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0710673A3 (en) | 1990-05-21 | 1996-08-07 | Toppan Printing Co Ltd | Cyclodextrin derivatives |
| US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
| US5430057A (en) | 1993-09-30 | 1995-07-04 | Board Of Regents, The University Of Texas System | Parenteral busulfan for treatment of malignant disease |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| EP0889056B1 (en) | 1997-07-01 | 2006-04-12 | Pfizer Products Inc. | Process for making a cyclodextrin |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| JP2006500387A (ja) | 2002-08-15 | 2006-01-05 | 雲清 劉 | 固形ナノ医薬およびその調製方法 |
| AU2003275329B2 (en) | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
| KR20060096490A (ko) | 2003-10-31 | 2006-09-11 | 더 유니버시티 오브 캔사스 | 술포알킬 에테르-알킬 에테르 시클로덱스트린 유도체 |
| US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| ES2364491T5 (es) | 2005-10-26 | 2015-02-19 | Cydex Pharmaceuticals, Inc. | Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas |
| US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
| JP2009517402A (ja) | 2005-11-28 | 2009-04-30 | ディー． ロウェ，バーノン | 腎毒性の低減に有用な組成物及びその使用方法 |
| CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
| WO2008067027A2 (en) * | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
| MX357677B (es) * | 2009-05-29 | 2018-07-19 | Cydex Pharmaceuticals Inc | Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas. |
| KR20240119191A (ko) * | 2012-05-08 | 2024-08-06 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
| CN105726467A (zh) * | 2014-12-09 | 2016-07-06 | 四川科瑞德制药有限公司 | 一种白消安注射液及其制备方法 |
-
2018
- 2018-05-02 JP JP2019560139A patent/JP7204670B2/ja active Active
- 2018-05-02 US US15/969,561 patent/US20180318249A1/en not_active Abandoned
- 2018-05-02 WO PCT/US2018/030728 patent/WO2018204535A1/en not_active Ceased
- 2018-05-02 EP EP18794455.8A patent/EP3618825A4/en active Pending
- 2018-05-02 AU AU2018263924A patent/AU2018263924B2/en active Active
- 2018-05-02 BR BR112019023074A patent/BR112019023074A2/pt active Search and Examination
- 2018-05-02 CN CN201880044721.9A patent/CN110831588B/zh active Active
- 2018-05-02 CA CA3062308A patent/CA3062308A1/en active Pending
- 2018-05-02 KR KR1020197035588A patent/KR20190141244A/ko not_active Ceased
- 2018-05-02 MX MX2019013053A patent/MX2019013053A/es unknown
-
2019
- 2019-11-01 MX MX2023000348A patent/MX2023000348A/es unknown
-
2022
- 2022-09-21 US US17/949,970 patent/US20230255919A1/en not_active Abandoned
- 2022-12-28 JP JP2022212559A patent/JP7597778B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019135196A (ru) | 2021-06-03 |
| MX2023000348A (es) | 2023-02-13 |
| WO2018204535A1 (en) | 2018-11-08 |
| US20230255919A1 (en) | 2023-08-17 |
| EP3618825A1 (en) | 2020-03-11 |
| EP3618825A4 (en) | 2021-01-20 |
| JP7204670B2 (ja) | 2023-01-16 |
| JP2020518608A (ja) | 2020-06-25 |
| MX2019013053A (es) | 2020-02-07 |
| US20180318249A1 (en) | 2018-11-08 |
| CN110831588A (zh) | 2020-02-21 |
| AU2018263924A1 (en) | 2019-11-21 |
| JP7597778B2 (ja) | 2024-12-10 |
| JP2023026562A (ja) | 2023-02-24 |
| CN110831588B (zh) | 2023-06-27 |
| CA3062308A1 (en) | 2018-11-08 |
| RU2019135196A3 (cg-RX-API-DMAC7.html) | 2021-07-28 |
| KR20190141244A (ko) | 2019-12-23 |
| AU2018263924B2 (en) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017027831A2 (pt) | derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| BR112018075284A2 (pt) | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
| UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
| BR112018010720A8 (pt) | agonistas do receptor de apelina e métodos de uso | |
| BR112018075433A2 (pt) | derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112016029906A8 (pt) | formulação líquida, uso de formulação terapêutica líquida, uso de formulação terapêutica líquida injetável, método de melhoria da estabilidade de uma formulação proteica líquida e método de melhoria de um processo relacionado a proteínas | |
| BR112018014536A2 (pt) | derivados de amônio, um processo para sua preparação e composições farmacêuticas contendo os mesmos | |
| BR112015005168A2 (pt) | Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos | |
| BR112017010720A2 (pt) | gel aquoso ou alcoólico aquoso de filossilicatos sintéticos como agente de viscosidade, de efeito matificante e/ou agente homogeneizador de aplicação | |
| BR112017009405A2 (pt) | composições antibióticas. | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| BR112016023851A2 (pt) | ?composição de revestimento de duas partes e método para revestir uma superfície? | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma | |
| BR112017016311A2 (pt) | derivados de 9h-pirrolo-dipiridina | |
| BR112019006853A2 (pt) | composição farmacêutica líquida | |
| BR112016000563A2 (pt) | Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica | |
| CL2017001592A1 (es) | Complejos radiofarmacéuticos. | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| BR112018010945A2 (pt) | formulações com degradação de polissorbato reduzida | |
| BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |